Department of Diagnostics and Public Health,
Section of Pathology,
Department of Diagnostics and Public Health, Section of Pathology
Michele Simbolo is a biotechnologist in the Department of Diagnostic and Public Health , University of Verona, Italy. He received his undergraduate degree from University of Naples "Federico II" of Italy, and a Ph.D. from the University of Verona, Italy.
During Dr. Simbolo’s training he developed a keen focus on next generation sequencing technologies, in particular Solid and Ion Torrent platforms. His research was focused on solid tumors genomic characterization. As a post-doctoral fellow (2015 to 2017) in Aldo Scarpa’s lab at the ARC-NET, University of Verona, Italy, he developed new diagnostic tools to identify pancreatic cancer predisposition. He's been hired to University of Verona, Italy, as a laboratory technician. Here he continues the development of new diagnostic tools and the genomic characterization of rare tumors.
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association , 2014 | Pubmed ID: 24272205
High-throughput mutation profiling improves diagnostic stratification of sporadic medullary thyroid carcinomas.
Virchows Archiv : an international journal of pathology Jul, 2014 | Pubmed ID: 24828033
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups.
Oncotarget May, 2014 | Pubmed ID: 24867389
Reporting tumor molecular heterogeneity in histopathological diagnosis.
PloS one , 2014 | Pubmed ID: 25127237
Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy.
Anti-cancer drugs Apr, 2015 | Pubmed ID: 25569703
Next-generation sequencing for genetic testing of familial colorectal cancer syndromes.
Hereditary cancer in clinical practice , 2015 | Pubmed ID: 26300997
A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics.
Cancer discovery Dec, 2015 | Pubmed ID: 26446169
New genomic landscapes and therapeutic targets for biliary tract cancers.
Frontiers in bioscience (Landmark edition) Jan, 2016 | Pubmed ID: 26709801
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Oncotarget Jan, 2016 | Pubmed ID: 26745875
Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.
The Journal of pathology 03, 2017 | Pubmed ID: 27873319
Whole-genome landscape of pancreatic neuroendocrine tumours.
Nature 03, 2017 | Pubmed ID: 28199314
Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.
Journal of hepatology 05, 2018 | Pubmed ID: 29360550
Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm.
Virchows Archiv : an international journal of pathology Apr, 2018 | Pubmed ID: 29388013
Frequent fusions in Caucasian pulmonary mucinous adenocarcinoma predicted by Phospho-ErbB3 expression.
Oncotarget Feb, 2018 | Pubmed ID: 29515761
Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma.
Scientific reports 05, 2018 | Pubmed ID: 29740198
Centrosome Linker-induced Tetraploid Segregation Errors Link Rhabdoid Phenotypes and Lethal Colorectal Cancers.
Molecular cancer research : MCR 09, 2018 | Pubmed ID: 29784668
Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 11, 2018 | Pubmed ID: 30149143
ERG alterations and mTOR pathway activation in primary prostate carcinomas developing castration-resistance.
Pathology, research and practice Oct, 2018 | Pubmed ID: 30190183
Mutational and copy number asset of primary sporadic neuroendocrine tumors of the small intestine.
Virchows Archiv : an international journal of pathology Dec, 2018 | Pubmed ID: 30219970
Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas.
The Journal of pathology Jan, 2019 | Pubmed ID: 30306561
Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis.
Pancreas 01, 2019 | Pubmed ID: 30451797
Gene Expression Profiling of Lung Atypical Carcinoids and Large Cell Neuroendocrine Carcinomas Identifies Three Transcriptomic Subtypes with Specific Genomic Alterations.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Sep, 2019 | Pubmed ID: 31085341
Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?
HPB : the official journal of the International Hepato Pancreato Biliary Association May, 2019 | Pubmed ID: 31122820
Exploring the molecular and biological background of lung neuroendocrine tumours.
Journal of thoracic disease May, 2019 | Pubmed ID: 31245083
Ultra-Mutation in Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment.
Cancers Aug, 2019 | Pubmed ID: 31480372
Glioblastoma with tumor-to-tumor metastasis from lung adenocarcinoma.
Neuropathology : official journal of the Japanese Society of Neuropathology Sep, 2019 | Pubmed ID: 31523853
Copyright © 2025 MyJoVE Corporation. All rights reserved
We use cookies to enhance your experience on our website.
By continuing to use our website or clicking “Continue”, you are agreeing to accept our cookies.